Jeil Pharma Holdings Inc (KRX:002620)
8,140.00
+110.00 (1.37%)
At close: Oct 31, 2025
Jeil Pharma Holdings Revenue
Jeil Pharma Holdings had revenue of 159.78B KRW in the quarter ending June 30, 2025, a decrease of -18.90%. This brings the company's revenue in the last twelve months to 735.79B, down -6.10% year-over-year. In the year 2024, Jeil Pharma Holdings had annual revenue of 779.82B, down -3.01%.
Revenue (ttm)
735.79B
Revenue Growth
-6.10%
P/S Ratio
0.16
Revenue / Employee
19.89B
Employees
37
Market Cap
117.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 779.82B | -24.22B | -3.01% |
| Dec 31, 2023 | 804.04B | 11.08B | 1.40% |
| Dec 31, 2022 | 792.96B | 30.40B | 3.99% |
| Dec 31, 2021 | 762.57B | 571.30M | 0.07% |
| Dec 31, 2020 | 762.00B | 30.19B | 4.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |